Galera Therapeutics (Galera Therapeutics) Operating Cash Flow per Share : $-0.80 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics Operating Cash Flow per Share?

Galera Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-0.09. Galera Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.80.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 25.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Galera Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

GRTX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -32 Med: 4.6 Max: 50.1
Current: 25.1

During the past 7 years, Galera Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 50.10% per year. The lowest was -32.00% per year. And the median was 4.60% per year.

GRTX's 3-Year OCF Growth Rate is ranked better than
74.8% of 1234 companies
in the Biotechnology industry
Industry Median: 3.5 vs GRTX: 25.10

Galera Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Galera Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galera Therapeutics Operating Cash Flow per Share Chart

Galera Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-12.87

-2.39

-2.64

-1.60

-1.01

Galera Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.33	-0.25	-0.28	-0.18	-0.09

Competitive Comparison of Galera Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Galera Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Price-to-Operating-Cash-Flow falls into.

Galera Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Galera Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-44.848	/	44.549
	=	-1.01

Galera Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-4.791	/	54.392
	=	-0.09

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80

Galera Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Galera Therapeutics (Galera Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 134, Malvern, PA, USA, 19355

Website

https://www.galeratx.com

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.

Executives

Mark Bachleda	officer: Chief Commercial Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen	director, officer: President and CEO	7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy	officer: Chief Medical Officer	2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey	officer: See Remarks	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund	officer: Chief Medical Officer
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman	officer: Chief Accounting Officer	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p.	10 percent owner	C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p.	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025